🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Mirabegron

    Astellas Pharma Inc

    Overactive Bladder (OAB)

    phase 3 small molecule terminated

    1 trial
  2. Mirena 20 mikrogram/24 timmar intrauterint inlägg, Kyleena® 19,5 mg, intrauterint inlägg, Jaydess 13,5 mg, intrauterint inlägg

    The George Institute

    Post medical abortion contraception

    phase 3 small molecule active

    1 trial
  3. Mirikizumab

    Eli Lilly and Company

    Ulcerative Colitis

    phase 3 small molecule active

    2 trials
  4. Mirikizumab SC

    Eli Lilly and Company

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial
  5. Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial
  6. Mirikizumab, Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Crohn's Disease

    phase 3 small molecule active

    1 trial
  7. Mirikizumab, Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Crohn’s Disease

    phase 3 small molecule active

    1 trial
  8. Mirikizumab, Tirzepatide, to match Tirzepatide, Tirzepatide, Tirzepatide, Mirikizumab, Tirzepatide, Tirzepatide, Tirzepatide

    Eli Lilly Co.

    Obesity or Overweight, Ulcerative Colitis

    phase 3 small molecule active

    1 trial
  9. Mirvetuximab Soravtansine

    AbbVie

    Epithelial Ovarian Cancer

    phase 3 small molecule completed

    1 trial
  10. Mirvetuximab soravtansine plus Bevacizumab

    AbbVie

    Ovarian Cancer

    phase 3 small molecule active

    1 trial
  11. Mitizodone Phosphate tablets

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Depressive Disorder, Major

    phase 3 small molecule active

    1 trial
  12. Modiodal 100 mg tabletten, PLACEBO

    Disc Medicine

    Inflammatory bowel disease, Fatigue

    phase 3 small molecule active

    1 trial
  13. Molnupiravir Matching placebo tablets, molnupiravir

    Merck Sharp and Dohme

    SARS-CoV-2 (COVID-19) infection

    phase 3 small molecule active

    1 trial
  14. Mometasonfuroaat Teva 50 microgram/verstuiving, neusspray, suspensie, Mometasonfuroat-ratiopharm® 50 Mikrogramm/Sprühstoß Nasenspray, Suspension, Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection., Fasenra 30 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Severe CRSwNP patients with asthma.

    phase 3 small molecule active

    1 trial
  15. Monalizumab, Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung, CETUXIMAB

    AstraZeneca AB

    Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor

    phase 3 small molecule active

    1 trial
  16. Mosunetuzumab, Mosunetuzumab

    Hoffmann-La Roche

    NA

    phase 3 small molecule active

    1 trial
  17. Mounjaro 5 mg solution for injection in pre-filled pen, cagrilintide semaglutide, cagrilintide semaglutide, Mounjaro 2.5 mg solution for injection in pre-filled pen, cagrilintide semaglutide

    NovoThirteen

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial
  18. Multi-centre, Open-label Trial to Assess the SaFety, Pharmacodynamics, Efficacy and Pharmacokinetics of PegunigaLsidase Alfa in Patients from 2 Years to Less Than 18 Years of Age with Confirmed FabrY Disease (FLY)

    Chiesi Farmaceutici S.p.A

    Fabry's disease

    phase 3 other active

    1 trial
  19. Muraglitazar

    Bristol-Myers Squibb

    Diabetes, Type 2

    phase 3 small molecule completed

    1 trial
  20. Mycofit, 250 mg, kapsułki twarde, volrustomig, Saline, Remsima 100 mg powder for concentrate for solution for infusion

    AstraZeneca AB

    Locally advanced cervical cancer

    phase 3 small molecule active

    1 trial
  21. Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, Lynparza 100 mg film-coated tablets, Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Imfinzi 50 mg/ml, Lynparza 100 mg, Lynparza 150 mg, Myfenax 250 mg hard capsules, Flixabi 100 mg p

    AstraZeneca AB

    Endometrial Cancer

    phase 3 small molecule active

    1 trial
  22. N-Acetyl-L-Leucine, granules for suspension

    Intrabio Ireland Limited

    CACNA1A Disorders

    phase 3 small molecule active

    1 trial
  23. N-Acetylcysteine

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 3 small molecule completed

    2 trials
  24. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources